PEPG NASDAQ
PepGen Inc.
1W: -7.8%
1M: -3.9%
3M: +36.1%
YTD: -65.3%
1Y: -44.7%
3Y: -54.5%
$2.60
+0.11 (+4.42%)
After Hours: $2.58 (-0.02, -0.58%)
Weekly Expected Move ±12.7%
$2
$2
$3
$3
$3
Credit Risk of going bust: higher than 85% of companies Debt: 8.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 98%), PepGen Inc. would be worth roughly what it owes.
Total debt $16.1M against a stock market value of $172.2M.
Distance to default 2.15 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $6.4M (short-term plus half of long-term), stock volatility 126.1%; Altman Z'' -1.75. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 98%), PepGen Inc. would be worth roughly what it owes.
Total debt $16.1M against a stock market value of $172.2M.
Distance to default 2.15 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $6.4M (short-term plus half of long-term), stock volatility 126.1%; Altman Z'' -1.75. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$172.2M
52W Range1.31-7.8
Volume906,708
Avg Volume953,009
Beta2.01
Dividend—
Analyst Ratings
Company Info
CEOJames McArthur
Employees57
SectorHealthcare
IndustryBiotechnology
IPO Date2022-05-06
Websitepepgen.com
321 Harrison Avenue
Boston, MA 02118
US
Boston, MA 02118
US
781-797-0979
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Latest News
PepGen, Inc. $PEPG Shares Bought by Squarepoint Ops LLC
PepGen, Inc. $PEPG Shares Sold by Bank of America Corp DE
BlackRock Inc. Buys Shares of 1,304,262 PepGen, Inc. $PEPG
ADAR1 Capital Management LLC Acquires New Shares in PepGen, Inc. $PEPG
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Wyman Lisa | A-Award | 34,000 | $1.79 | 2026-06-18 |
| Resnick Joshua | A-Award | 34,000 | $1.79 | 2026-06-18 |
| Mayer Howard | A-Award | 34,000 | $1.79 | 2026-06-18 |
| Finer Mitchell H. | A-Award | 34,000 | $1.79 | 2026-06-18 |
| Dable Habib J | A-Award | 34,000 | $1.79 | 2026-06-18 |